‘SUITX by Ottobock’ Sets New Standards in Exoskeleton Technology
New back-support exoskeleton for logistics, new business unit, new umbrella brandEMERYVILLE, CA / ACCESSWIRE / October 12, 2023 / Today...
Prosthetic
BioNTX Names Osteal Therapeutics 2023 Rising Star
President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award...
Renowned Plastic Surgeon Dr. Lawrence Gray Expands Services to Enhance Aesthetic Beauty and Confidence in Portsmouth, NH
PORTSMOUTH, NH / ACCESSWIRE / September 27, 2023 / Atlantic Plastic Surgery Center is delighted to announce the expansion of...
PHAXIAM Provides Business and Financial Update For the First Half of 2023
PHAXIAM Provides Business and Financial UpdateFor the First Half of 2023 Conference call and webcast (English) on Monday, September 25,...
Osteal Therapeutics Closes $23M Series C Financing
Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corp., HM...
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the...
Thought Leadership & Innovation Foundation (TLI) Showcases Data-Driven Healthcare Solutions at 2023 AOPA National Assembly
MCLEAN, Va.--(BUSINESS WIRE)--Thought Leadership & Innovation Foundation (TLI), a not-for-profit organization that works at the nexus of science, technology and...
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
Signati™️ Medical, Inc. Announces Dr. LeRoy Jones Has Been Appointed to Its Board of Directors
Providence, RI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Signati™️ Medical, Inc. announced today that Dr. LeRoy Jones has been appointed...
Global Transcatheter Heart Valve Market Set to Reach $15.14 Billion by 2030 with a Strong CAGR of 12.73% – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Transcatheter Heart Valve Replacement Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company...
Medical Thought Leaders to Convene in Ukraine for Collaborative Summit
COLUMBUS, OHIO / ACCESSWIRE / July 18, 2023 / An International Healthcare Summit has been scheduled in Kyiv, Ukraine for...
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the...
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update
YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD Pixium Vision to receive interactive communication...
Quipt Home Medical Reports Record First Quarter Fiscal 2023 Financial Results Posting Positive Net Income, Revenue Growth of 38% and Adjusted EBITDA Growth of 50%
Posts Strong Adjusted EBITDA Margin of 22% and Sequential Organic Growth of 2%CINCINNATI, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Quipt...
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued execution to advance exebacase and CF-370 into new clinical studiesYONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation...